`Case 1:20-cv-00393-LO-TCB Document 1007-3 Filed 02/11/22 Page 1 of 4 PagelD# 28149
`
`EXHIBIT C
`EXHIBIT C
`
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1007-3 Filed 02/11/22 Page 2 of 4 PageID# 28150
`
`
`
`
` 1
`
`
` 1 UNITED STATES INTERNATIONAL TRADE COMMISSION
`
` 2 Washington, D.C.
`
` 3 Before the Honorable Clark S. Cheney
`
` 4 Administrative Law Judge
`
` 5
`
` 6 ------------------------------x
`
` 7 In the Matter of Investigation No.
`
` 8
`
` 9 CERTAIN TOBACCO HEATING ARTICLES 337-TA-1199
`
` 10 AND COMPONENTS THEREOF
`
` 11 ------------------------------x
`
` 12
`
` 13
`
` 14
`
` 15
`
` 16 Monday, January 25, 2021
`
` 17
`
` 18 EVIDENTIARY HEARING - VOLUME I - REMOTE
`
` 19
`
` 20
`
` 21 The parties met, via remote videoconferencing, pursuant to
`
` 22 notice of the Administrative Law Judge, at 9:00 a.m.
`
` 23 Eastern.
`
` 24
`
` 25 Reported by: Karen Brynteson, RMR, CRR, FAPR
`
`
`
`
`
`
`Heritage Reporting Corporation
`(202) 628-4888
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1007-3 Filed 02/11/22 Page 3 of 4 PageID# 28151
`
`
`
` 99
`
`
` 1 correct?
`
` 2 A. They are. They're called e-cigarettes, vape
`
` 3 products, or ENDS.
`
` 4 Q. Okay. And you talked a little bit about PMTAs
`
` 5 during your direct examination. And Reynolds has put in a
`
` 6 PMTA for its Solo product and its Vibe product, correct?
`
` 7 A. We have, yes.
`
` 8 Q. All right. It has also put in PMTAs for its
`
` 9 other e-cigarette devices, the Ciro and the Alto, correct?
`
` 10 A. Among other products, yes, that's correct.
`
` 11 Q. Okay. And you agree, Dr. Figlar, that if the
`
` 12 FDA denies Reynolds' PMTA applications for its Vuse
`
` 13 products, then Reynolds has to pull those products from the
`
` 14 market, correct?
`
` 15 A. If -- if that were the case, that would be true,
`
` 16 yes.
`
` 17 Q. All right.
`
` 18 A. We don't feel that that's likely, but that would
`
` 19 be the case.
`
` 20 Q. I understand. But, Dr. Figlar, you don't know
`
` 21 if the FDA is going to authorize Reynolds' PMTAs for its
`
` 22 Vuse products, correct?
`
` 23 A. No, I don't know it but we're very, very
`
` 24 confident, obviously, in our applications. But, you know,
`
` 25 we don't -- we don't know until the FDA makes a judgment.
`
`
`
`
`
`
`Heritage Reporting Corporation
`(202) 628-4888
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1007-3 Filed 02/11/22 Page 4 of 4 PageID# 28152
`
`
`
` 100
`
`
` 1 Q. Right. So, Dr. Figlar, it's possible that the
`
` 2 Vibe and the Solo domestic industry products will have to
`
` 3 be removed from the market this year, right?
`
` 4 A. This year, I'm not sure. It depends on when the
`
` 5 FDA is going to make a decision before one would have to,
`
` 6 you know, remove products from the market. But, you know,
`
` 7 we will see.
`
` 8 Q. Well, if the FDA denies the applications,
`
` 9 Reynolds is going to pull the products, correct?
`
` 10 A. Well, obviously I think Reynolds would -- would
`
` 11 run the course of -- of administrative review, but -- but,
`
` 12 yes, if ultimately the FDA makes that decision, then we
`
` 13 would have to remove those products from the market.
`
` 14 Q. Okay. Now, there's another FDA term that's been
`
` 15 discussed in this case called an MRTPA, correct?
`
` 16 A. I suppose, yes, I know what an MRTPA is, yes.
`
` 17 Q. Right. An MRTPA stands for Modified Risk
`
` 18 Tobacco Product Application, correct?
`
` 19 A. That is correct.
`
` 20 Q. Right. And if an MRT application is granted, a
`
` 21 company can advertise a tobacco product as, for instance, a
`
` 22 reduced risk or a reduced exposure product, correct?
`
` 23 A. It depends on what the FDA decides with regard
`
` 24 to those advertising claims, but, yes, there's a G-1 and
`
` 25 G-2 path, exposure or risk.
`
`
`
`
`
`
`Heritage Reporting Corporation
`(202) 628-4888
`
`